Acadian Asset Management LLC bought a new stake in shares of Chimerix Inc (NASDAQ:CMRX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 60,411 shares of the biopharmaceutical company’s stock, valued at approximately $280,000.
A number of other institutional investors have also made changes to their positions in CMRX. Rhumbline Advisers raised its stake in Chimerix by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 48,541 shares of the biopharmaceutical company’s stock valued at $265,000 after acquiring an additional 3,300 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Chimerix by 3.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 253,367 shares of the biopharmaceutical company’s stock valued at $1,381,000 after acquiring an additional 8,287 shares in the last quarter. Alliancebernstein L.P. raised its stake in Chimerix by 8.3% during the 2nd quarter. Alliancebernstein L.P. now owns 70,200 shares of the biopharmaceutical company’s stock valued at $383,000 after acquiring an additional 5,400 shares in the last quarter. Teachers Advisors LLC raised its stake in Chimerix by 53.5% during the 2nd quarter. Teachers Advisors LLC now owns 107,179 shares of the biopharmaceutical company’s stock valued at $584,000 after acquiring an additional 37,361 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Chimerix by 10.4% during the 2nd quarter. Northern Trust Corp now owns 696,440 shares of the biopharmaceutical company’s stock valued at $3,795,000 after acquiring an additional 65,335 shares in the last quarter. 70.40% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have weighed in on CMRX shares. HC Wainwright assumed coverage on Chimerix in a research note on Friday. They set a “buy” rating and a $10.00 target price on the stock. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research note on Friday, November 10th. Finally, ValuEngine raised Chimerix from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $7.06.
Shares of Chimerix Inc (CMRX) opened at $4.65 on Tuesday. Chimerix Inc has a 12 month low of $4.17 and a 12 month high of $6.64. The company has a market capitalization of $219.14, a price-to-earnings ratio of -3.25 and a beta of 1.42.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.06. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. The company had revenue of $0.90 million for the quarter, compared to the consensus estimate of $0.81 million. sell-side analysts anticipate that Chimerix Inc will post -1.6 earnings per share for the current year.
In other news, insider Linda M. Richardson sold 19,833 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 4.40% of the stock is currently owned by insiders.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix Inc (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.